Delivery Order SPE2DR25D2108-SPE2DR26F6SF1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,588.75 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens on December 30, 2025, with a completion date of December 31, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $30,762.29 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. The contract, awarded on December 11, 2025, with an ultimate completion date of December 12, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the prime contractor on this award. Repatha is a prescription medication used to...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injector pens, with a ceiling value of $4,309.83. The contract was competitively awarded without set-aside designation and is scheduled for completion by December 8, 2025. AmerisourceBergen will fulfill this order from its corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as one of the nation's largest...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,386.25 on October 23, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of October 24, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is located. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $16,968.74 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of November 4, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $91,225.90 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and a...
- The Defense Logistics Agency awarded a delivery order valued at $8,921.19 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens on December 19, 2025, with completion targeted for December 22, 2025. This competitively awarded, firm fixed-price delivery order represents a small but critical pharmaceutical procurement supporting military and federal healthcare needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a primary...
- The Defense Logistics Agency awarded a delivery order valued at $3,258.30 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with performance in Conshohocken, Pennsylvania and completion targeted for December 3, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement and...
- The Defense Logistics Agency awarded a $80,596.93 delivery order contract to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and...
- The Defense Logistics Agency awarded a delivery order valued at $5,798.34 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on November 20, 2025, with a completion date of November 21, 2025, represents a non-set-aside competitive award supporting federal medical procurement requirements. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DR25D2108Indefinite Delivery Contract
- SPE2DR25D2108-SPE2DR26F6SF1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $31.2K to AmerisourceBergen Drug Corp on January 13, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector pens. The contract is competitively awarded with no set-aside designation and carries a firm fixed-price structure with an ultimate completion date of January 14, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc. (formerly AmerisourceBergen), one of the nation's largest pharmaceutical distributors serving federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of brand-name and generic medications, specialty pharmaceuticals, vaccines, and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Repatha is a PCSK9 inhibitor indicated for cholesterol management in patients with cardiovascular disease, representing the type of specialty pharmaceutical commodity that supports military treatment facilities and veteran healthcare programs under this strategic procurement vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.2k | 1/12/26 |